Corcept Therapeutics CORT -4.84% Get Free Report has outperformed the market over the past 20 years by 7.21% on an annualized ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 7.02%, which has investors questioning if this is right ...

Corcept Therapeutics saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, detailing the ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Pictet Asset Management Holding SA grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 13.8% during the 4th quarter, according to its most recent 13F filing ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Corcept Therapeutics saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, detailing the ...